

( (S (NP-SBJ-2 (NP Delmed Inc. 's)
	       top two officers)
     (VP (VP resigned)
	 and
	 (VP were
	     (VP succeeded
		 (NP *-2)
		 (PP by
		     (NP-LGS (NP executives)
			     (PP of
				 (NP (NP Fresenius USA Inc.)
				     and
				     (NP (NP its parent)
					 ,
					 (NP Fresenius AG)
					 ,
					 (NP (NP a major Delmed holder)
					     (SBAR (WHNP-1 that)
						   (S (NP-SBJ-3 *T*-1)
						      (VP has
							  (VP been
							      (VP negotiating
								  (S (NP-SBJ *-3)
								     (VP to
									 (VP acquire
									     (NP a controlling stake))))))))))))))))))
     .))
( (S (PP In
         (NP addition))
     ,
     (NP-SBJ (NP Delmed)
             ,
             (SBAR (WHNP-2 which)
                   (S (NP-SBJ *T*-2)
                      (VP makes and sells
                          (NP (NP a dialysis solution)
                              (VP used
                                  (NP *)
                                  (PP-LOC in 
					  (S-NOM (NP-SBJ *)
						 (VP treating
						     (NP kidney diseases)))))))))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP negotiations)
                          (PP about
                              (NP pricing))
                          (PP *ICH*-1))
                  (VP had
                      (VP collapsed
			  (PP-1 between
				(NP (NP it)
				    and
				    (NP (NP a major distributor)
					,
					(NP National Medical Care Inc)))))))))
     .))
( (S (NP-SBJ Delmed)
     (VP said
         (SBAR 0
               (S (NP-SBJ Robert S. Ehrlich)
                  (VP resigned
                      (PP-CLR as
			      (NP (NP chairman)
				  ,
				  (NP president)
				  and
				  (NP chief executive)))))))
     .))
( (S (NP-SBJ Mr. Ehrlich)
     (VP will
         (VP continue
             (PP-CLR as
		     (NP (NP a director)
			 and
			 (NP a consultant)))))
     .))
( (S (S-TPC-1 (NP-SBJ (NP Leslie I. Shapiro)
		      ,
		      (NP (NP chief operating officer)
			  and
			  (NP chief financial officer))
		      ,)
	      (ADVP also)
	      (VP resigned))
     ,
     (NP-SBJ the company)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ-1 Mr. Ehrlich)
     (VP was
         (VP succeeded
             (NP *-1)
             (PP-CLR as
		     (NP chairman))
             (PP by
                 (NP-LGS (NP Gerd Krick)
			 ,
			 (NP (NP a director)
			     (PP of
				 (NP (NP Fresenius)
				     ,
				     (NP a
					 (ADJP West German)
					 pharmaceutical concern))))))))
     .))
( (S (NP-SBJ-1 (NP Ben Lipps)
               ,
               (NP (NP president)
                   (PP of
                       (NP Fresenius USA)))
               ,)
     (VP was
         (VP named
             (S (NP-SBJ *-1)
		(NP-PRD (NP president)
			,
			(NP chief executive)
			and
			(NP chief operating officer)))))
     .))
( (S (NP-SBJ (NP None)
             (PP of
                 (NP the officials)))
     (VP was
         (ADJP-PRD available
                   (PP for
                       (NP comment))))
     .))
( (S (PP-LOC In
	     (NP (NP trading)
		 (PP-LOC on
			 (NP the American Stock Exchange))))
     ,
     (NP-SBJ Delmed)
     (VP closed
         (PP-CLR at
		 (NP 50 cents))
	 ,
	 (ADVP-CLR down
		   (NP 6.25 cents)))
     .))
( (S (NP-SBJ Fresenius)
     (VP owns
         (NP (NP (QP about 42)
		 %)
             (PP of
                 (NP (NP Delmed 's)
                     (ADJP fully diluted)
                     common stock))))
     .))
( (S (NP-SBJ The two companies)
     (VP have
         (VP been
             (VP discussing
                 (NP (NP a transaction)
                     (SBAR (WHPP-2 under
				   (WHNP which))
                           (S (NP-SBJ-3 Fresenius)
                              (VP would
                                  (VP buy
                                      (NP Delmed stock)
                                      (PP-CLR for
					      (NP cash))
				      (PP *T*-2)
				      (S-PRP (NP-SBJ *-3)
					     (VP to
						 (VP bring
						     (NP its beneficial ownership)
						     (PP-CLR to 
							     (NP (NP (QP between 70 % and 80 %)
								     *U*)
								 (PP of
								     (NP (NP Delmed 's)
									 (ADJP fully diluted)
									 common stock)))))))))))))))
     .))
( (S (NP-SBJ The transaction)
     (ADVP also)
     (VP would
         (VP combine
             (NP (NP Fresenius USA)
                 and
                 (NP Delmed))))
     .))
( (S (PP Under
         (NP the proposal))
     ,
     (NP-SBJ Delmed)
     (VP would
         (VP issue
             (NP (QP about 123.5 million) additional Delmed common shares)
             (PP-DTV to
		     (NP Fresenius))
             (PP-CLR at
		     (NP (NP an average price)
			 (PP of
			     (NP (NP (NP (QP about 65) cents)
				     (NP-ADV a share))
				 ,
				 (SBAR-ADV though 
					   (FRAG (PP under
						     (NP no circumstances))
						 (NP (NP (QP more than 75)
							 cents)
						     (NP-ADV a share))))))))))
     .))
( (S (NP-TMP Yesterday)
     ,
     (NP-SBJ Delmed)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 it)
                  ``
                  (VP continues
                      (S (NP-SBJ *-1)
                         (VP to
                             (VP explore
                                 (NP (NP the possibility)
                                     (PP of
                                         (NP (NP a combination)
                                             (PP with
                                                 (NP Fresenius USA))))))))))))
     .
     ''))
( (S (NP-SBJ It)
     (VP added
         (SBAR that
               (S (NP-SBJ (NP it)
                          (SBAR *EXP*-2))
                  (VP is
                      (ADJP-PRD apparent)
		      (SBAR-2 that
			      (S (NP-SBJ (NP any terms)
					 (PP of
					     (NP a combination)))
				 ``
				 (VP would
				     (VP be
					 (ADJP-PRD (ADJP substantially less favorable) 
						   (PP than
						       (NP (NP those)
							   (VP (ADVP-TMP previously)
							       announced
							       (NP *)))))))))))))
     .
     ''))
( (S (S-TPC-3 (SBAR-ADV While
			(S (NP-SBJ-1 (NP the discussions)
				     (PP between
					 (NP (NP Delmed)
					     and
					     (NP National Medical Care))))
			   (VP have
			       (VP been
				   (VP discontinued
				       (NP *-1))))))
	      ,
	      (NP-SBJ-2 Delmed)
	      (VP will
		  (VP continue
		      (S (NP-SBJ *-2)
			 (VP to
			     (VP supply
				 (NP dialysis products)
				 (PP-MNR through
					 (NP National Medical)))))
		      (SBAR-TMP after
				(S (NP-SBJ their exclusive agreement)
				   (VP ends
				       (PP-TMP in
					       (NP March 1990))))))))
     ,
     (NP-SBJ Delmed)
     (VP said
	 (SBAR 0
	       (S *T*-3)))
     .))
( (S (S-TPC-1 (PP In
		  (NP addition))
	      ,
	      (NP-SBJ Delmed)
	      (VP is
		  (VP exploring
		      (NP distribution arrangements)
		      (PP with
			  (NP Fresenius USA)))))
     ,
     (NP-SBJ Delmed)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
